pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
153
stories
20h
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
1d
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
2d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
2d
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
3d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
4d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
6d
Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
endpoints
6d
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
biopharma dive
6d
STAT+: PBMs agree to display TrumpRx drug prices
stat
6d
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
6d
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
6d
BMS welcomes new multiple myeloma drug as generics batter current portfolio
biospace
7d
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
fiercebiotech
7d
FDA approves Bristol Myers' multiple myeloma successor
endpoints
9d
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
9d
AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinois
endpoints
10d
Bristol Myers details new $2.3B manufacturing campus in Houston
endpoints
10d
BMS picks Texas for new $2.3B manufacturing campus
biospace
10d
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
11d
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
11d
Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetes
raps
13d
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
14d
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
14d
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
14d
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
15d
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
15d
Cardiac drug developer Braveheart banks more than $382M in IPO
biopharma dive
← prev
page 1 of 6
next →
